Tuesday, 17 November 2026European Markets

BERGENBIO Stock Over 28% Down In The Last 21 Sessions

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

(VIANEWS) - Shares of BERGENBIO (Oslo Børs Benchmark Index_GI: BGBIO.OL) dropped by a staggering 28.66% in 21 sessions from kr6.77 to kr4.83 at 11:25 EST on Tuesday, after two consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI is jumping 0.43% to kr1,163.74, following the last session's upward trend.

About BERGENBIO

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.

Earnings Per Share

As for profitability, BERGENBIO has a trailing twelve months EPS of kr-3.431.

Volume

Today's last reported volume for BERGENBIO is 45627 which is 71.69% below its average volume of 162246.

More news about BERGENBIO (BGBIO.OL).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

  1. Published before we listed source documents with each article.
  2. Published 28 Mar 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›